Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pioglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | RXRA | P19793 | 1/20 | 0.98 |
| ▸ | MPC2 | O95563 | 1/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pioglitazone SCHEMBL29364546 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL29593116 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162440 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL503083 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL4121 | 1.00 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL23534417 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL2332117 | 0.99 | PPARG (0.98) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL1162192 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL3689044 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| Pioglitazone SCHEMBL21843 | 0.99 | PPARG (1.00) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7162 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170082-A1 | HPDL INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | claimed |
| EP-3375452-B1 | USE OF LAMBDA INTERFERONS IN THE TREATMENT OF AN OBESITY-RELATED DISORDER, ATHEROSCLEROSIS OR A COAGULATION DISORDER | ANDREAKOS EVANGELOS (GR) | 2025-01-08 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| US-20240261447-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-08-08 | — | — | US | claimed |
| WO-2024126878-A1 | MULTIPURPOSE TELECOMMUNICATIONS BOOTH | ROSELLO CISCAR JOSE (ES) | 2024-06-20 | — | — | WO | claimed |
| US-20240148757-A1 | USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY | UNIV TEXAS (US) | 2024-05-09 | — | — | US | claimed |
| WO-2023009424-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO THE HEPATOPANCREATIC ANATOMICAL REGION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-02-02 | — | — | WO | claimed |
| US-20220340672-A1 | TNFRSF25-MEDIATED TREATMENTS OF IMMUNE DISEASES AND DISORDERS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-10-27 | — | — | US | claimed |
| WO-2022160022-A1 | LONG-LASTING RESORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND METHOD | LUIZ PERACCHI EDSON (BR) | 2022-08-04 | — | — | WO | claimed |
| WO-2003039519-A2 | DUAL CONTROLLED RELEASE DOSAGE FORM | OSMOTICA CORP. (VG) | 2003-05-15 | — | — | WO | claimed |
| EP-1307183-A2 | TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS | Pfizer Limited (GB) | 2003-05-07 | — | — | EP | claimed |
| WO-2003032646-A1 | VIDEO SURVEILLANCE SYSTEM FOR VEHICLES | MEDIA TRANS TECH SOLUTIONS, S.L. (ES) | 2003-04-17 | — | — | WO | claimed |
| US-20020165237-A1 | Treatment of the insulin resistance syndrome | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002013798-A2 | TREATMENT OF THE INSULIN RESISTANCE SYNDROME WITH SELECTIVE CGMP PDE5 INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | claimed |
| WO-2002004024-A1 | COMPOSITION FOR THE TREATMENT OF DIABETES | RIEVELEY ROBERT B (CA) | 2002-01-17 | — | — | WO | claimed |
| US-6291495-B1 | Method and composition for the treatment of diabetes | RIEVELEY ROBERT B (CA) | 2001-09-18 | — | — | US | claimed |
| US-6153632-A | FOR TREATING DIABETES MELLITUS BY INCORPORATING A THERAPEUTIC AMOUNT OF ONE OR MORE INSULIN SENSITIZERS ALONG WITH ONE OR MORE OF AN ORALLY INGESTED INSULIN, AN INJECTED INSULIN, A SULFONYLUREA, A BIGUANIDE OR AN ALPHA-GLUCOSIDASE INHIBITOR | RIEVELEY, CHERYL ANNE (CA) | 2000-11-28 | — | — | US | claimed |
| WO-1999062047-A1 | PUBLICITY MEDIUM FOR MICROPHONES | PIVOT PUBLICIDAD, S.A. (ES) | 1999-12-02 | — | — | WO | claimed |
| WO-1997010705-A1 | WASHBASIN-TOILET-RESIDENCE FOR ANIMALS | CASTELLS TARAFA JOSE (ES) | 1997-03-27 | — | — | WO | claimed |